Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348366 | 0.88 | DDB1 (0.49) | DDB1CRBNGSPT1ALDH1A1CHRM2 | |
| SCHEMBL29348348 | 0.85 | CRBN (0.46) | DDB1CRBNPOLBGSPT1 | |
| SCHEMBL31068241 | 0.82 | DDB1 (0.56) | DDB1CRBNALDH1A1CHRM2OPRM1 | |
| SCHEMBL29348362 | 0.82 | CRBN (0.55) | DDB1CRBNIKZF3 | |
| SCHEMBL29348473 | 0.80 | KMT2A (0.41) | DDB1CRBNALDH1A1 | |
| SCHEMBL31068201 | 0.80 | KMT2A (0.41) | DDB1CRBNALDH1A1 | |
| SCHEMBL31068261 | 0.80 | DDB1 (0.47) | DDB1CRBNGSPT1 | |
| SCHEMBL29348711 | 0.80 | DDB1 (0.47) | DDB1CRBNGSPT1 | |
| SCHEMBL29348424 | 0.79 | CRBN (0.45) | DDB1CRBNALDH1A1CHRM2OPRM1 | |
| SCHEMBL31068095 | 0.79 | CRBN (0.46) | DDB1CRBNGSPT1ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | DDB1 1125/4885CRBN 144/4885POLB 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.